Quick Answer
Oncotelic Therapeutics, Inc. reported R&D Expense of $61.1 thousand for fiscal year 2023.
Oncotelic Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2023 | $61.1K | -91.9% |
| 2022 | $756.9K | -79.3% |
| 2021 | $3.66M | -15.0% |
| 2020 | $4.30M | +213.6% |
| 2019 | $1.37M | +111.2% |
| 2018 | $649.8K | -93.8% |
| 2017 | $10.47M | +19.5% |
| 2016 | $8.76M | -3.5% |
| 2015 | $9.09M | +22.7% |
| 2014 | $7.41M | +103.7% |
| 2013 | $3.64M | +3.2% |
| 2012 | $3.52M | -33.4% |
| 2011 | $5.29M | -56.3% |
| 2010 | $12.11M | -45.6% |
| 2009 | $22.26M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| June 30, 2025 | $297.00 | +17.9% | +0.0% |
| March 31, 2025 | $297.00 | -38.1% | -38.1% |
| September 30, 2024 | $480.00 | -97.7% | +90.5% |
| June 30, 2024 | $252.00 | — | -47.5% |
| March 31, 2024 | $480.00 | -99.3% | -97.7% |
| September 30, 2023 | $21.2K | +1148.3% | -67.8% |
| March 31, 2023 | $65.9K | -88.6% | +3777.4% |
| September 30, 2022 | $1.7K | -99.7% | -98.4% |
- Oncotelic Therapeutics, Inc. showed a decrease of -91.9% in R&D Expense compared to the prior fiscal year.
- Over the 2009–2023 period, Oncotelic Therapeutics, Inc.’s r&d expense has declined by 99.7% (from $22.26 million to $61.1 thousand).
- The most recent figure is from Oncotelic Therapeutics, Inc.’s fiscal year 2023 report (Form 10-K), filed with the SEC on April 12, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: